Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Decartes-08

Phase 3Biologic

CCartesian Therapeutics

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Myasthaenia GravisActive, not recruiting

Myasthaenia GravisPhase 3

Active, not recruiting

Timeline

Expected Milestones

Q3 2027

Phase 3Active, not recruiting

Myasthaenia Gravis

NCT06799247

Clinical

Trials by Indication[1]

Myasthaenia Gravis1 trial

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Descartes-08 in Patients With Generalized Myasthenia Gravis (MG)

Active, not recruiting·CCartesian Therapeutics·Phase 3·NCT06799247·128 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Decartes-08. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Decartes-08 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Decartes-08. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cartesian Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: CCartesian Therapeutics

Related News